Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

Safety and Efficacy of Allogeneic NK Cell Therapy for Recurrent/Refractory Elderly AML

Authors not listed

The Second Hospital of Shandong University · 2020

Abstract

The aim of this investigation was to assess safety and efficacy of allogenic NK cells therapy for recurrent refractory elderly AML.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-03 MST

Cite this

APA
Anonymous. (2020). Safety and Efficacy of Allogeneic NK Cell Therapy for Recurrent/Refractory Elderly AML. <em>The Second Hospital of Shandong University</em>. https://clinicaltrials.gov/study/NCT04599452
Vancouver
Anonymous. Safety and Efficacy of Allogeneic NK Cell Therapy for Recurrent/Refractory Elderly AML. The Second Hospital of Shandong University. 2020.
BibTeX
@misc{anon2020Safety, title = {Safety and Efficacy of Allogeneic NK Cell Therapy for Recurrent/Refractory Elderly AML}, author = {Anonymous}, journal = {The Second Hospital of Shandong University}, year = {2020}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings